UBS Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $80M | Sell |
367,700
-186,600
| -34% | -$41.4M | 0.01% | 1219 |
|
|
2025
Q4 | $127M | Sell |
554,300
-22,600
| -4% | -$5.15M | 0.02% | 847 |
|
|
2025
Q3 | $134M | Buy |
576,900
+113,400
| +24% | +$23.1M | 0.02% | 822 |
|
|
2025
Q2 | $86M | Sell |
463,500
-501,100
| -52% | -$93.1M | 0.01% | 1080 |
|
|
2025
Q1 | $202M | Buy |
964,600
+227,200
| +31% | +$44.2M | 0.04% | 498 |
|
|
2024
Q4 | $131M | Sell |
737,400
-73,400
| -9% | -$13.5M | 0.02% | 744 |
|
|
2024
Q3 | $160M | Buy |
810,800
+207,100
| +34% | +$38.7M | 0.03% | 502 |
|
|
2024
Q2 | $104M | Sell |
603,700
-105,600
| -15% | -$17.5M | 0.03% | 638 |
|
|
2024
Q1 | $129M | Sell |
709,300
-390,812
| -36% | -$67.4M | 0.03% | 528 |
|
|
2023
Q4 | $170M | Buy |
1,100,112
+265,712
| +32% | +$38.7M | 0.05% | 361 |
|
|
2023
Q3 | $124M | Buy |
834,400
+137,200
| +20% | +$20.1M | 0.04% | 418 |
|
|
2023
Q2 | $93.9M | Buy |
697,200
+70,500
| +11% | +$10.3M | 0.03% | 523 |
|
|
2023
Q1 | $99.9M | Sell |
626,700
-42,000
| -6% | -$6.42M | 0.04% | 459 |
|
|
2022
Q4 | $108M | Buy |
668,700
+353,300
| +112% | +$54.2M | 0.04% | 461 |
|
|
2022
Q3 | $42.3M | Sell |
315,400
-38,400
| -11% | -$5.51M | 0.02% | 778 |
|
|
2022
Q2 | $54.2M | Sell |
353,800
-920,400
| -72% | -$141M | 0.02% | 690 |
|
|
2022
Q1 | $207M | Sell |
1,274,200
-103,474
| -8% | -$15M | 0.07% | 285 |
|
|
2021
Q4 | $187M | Buy |
1,377,674
+800,813
| +139% | +$94.6M | 0.05% | 363 |
|
|
2021
Q3 | $62.2M | Buy |
576,861
+208,026
| +56% | +$23.8M | 0.02% | 753 |
|
|
2021
Q2 | $41.5M | Buy |
368,835
+47,313
| +15% | +$5.33M | 0.01% | 969 |
|
|
2021
Q1 | $34.8M | Sell |
321,522
-48,178
| -13% | -$5.15M | 0.01% | 1062 |
|
|
2020
Q4 | $39.6M | Buy |
369,700
+76,200
| +26% | +$7.32M | 0.01% | 920 |
|
|
2020
Q3 | $25.7M | Sell |
293,500
-200
| -0.1% | -$18.8K | 0.01% | 1010 |
|
|
2020
Q2 | $28.8M | Sell |
293,700
-156,000
| -35% | -$13.7M | 0.01% | 875 |
|
|
2020
Q1 | $34.3M | Sell |
449,700
-182,322
| -29% | -$15.5M | 0.02% | 713 |
|
|
2019
Q4 | $56M | Buy |
632,022
+317,222
| +101% | +$26.3M | 0.02% | 718 |
|
|
2019
Q3 | $23.8M | Sell |
314,800
-70,200
| -18% | -$4.81M | 0.01% | 1121 |
|
|
2019
Q2 | $28M | Sell |
385,000
-739,940
| -66% | -$58.2M | 0.01% | 993 |
|
|
2019
Q1 | $90.7M | Buy |
1,124,940
+1,056,200
| +1,537% | +$86.4M | 0.04% | 410 |
|
|
2018
Q4 | $6.34M | Buy |
+68,740
| New | +$6.04M | ﹤0.01% | 1953 |
|
|
2018
Q2 | – | Sell |
-24,900
| Closed | -$2.36M | – | 7934 |
|
|
2018
Q1 | $2.36M | Sell |
24,900
-27,000
| -52% | -$2.97M | ﹤0.01% | 2998 |
|
|
2017
Q4 | $5.02M | Buy |
51,900
+39,208
| +309% | +$3.7M | ﹤0.01% | 2352 |
|
|
2017
Q3 | $1.13M | Buy |
12,692
+8,297
| +189% | +$632K | ﹤0.01% | 3611 |
|
|
2017
Q2 | $319K | Buy |
4,395
+1,760
| +67% | +$118K | ﹤0.01% | 4449 |
|
|
2017
Q1 | $172K | Sell |
2,635
-330,500
| -99% | -$20.8M | ﹤0.01% | 4731 |
|
|
2016
Q4 | $20.9M | Buy |
333,135
+227,950
| +217% | +$13.9M | 0.01% | 996 |
|
|
2016
Q3 | $6.63M | Buy |
105,185
+100,220
| +2,019% | +$6.49M | ﹤0.01% | 1763 |
|
|
2016
Q2 | $307K | Buy |
4,965
+2,823
| +132% | +$172K | ﹤0.01% | 4242 |
|
|
2016
Q1 | $122K | Sell |
2,142
-85,458
| -98% | -$4.76M | ﹤0.01% | 4828 |
|
|
2015
Q4 | $5.19M | Sell |
87,600
-83,100
| -49% | -$4.79M | ﹤0.01% | 1931 |
|
|
2015
Q3 | $9.29M | Sell |
170,700
-193,100
| -53% | -$12.6M | 0.01% | 1434 |
|
|
2015
Q2 | $24.4M | Buy |
363,800
+326,000
| +862% | +$21.3M | 0.02% | 852 |
|
|
2015
Q1 | $2.21M | Sell |
37,800
-707,000
| -95% | -$42.7M | ﹤0.01% | 2835 |
|
|
2014
Q4 | $48.7M | Buy |
+744,800
| New | +$47M | 0.03% | 547 |
|
Other funds holding ABBV
VCM
VPM
UBS Group's ABBV Position: Q1 2026 in Review
UBS Group increased its AbbVie (ABBV) stake by 33% in Q1 2026, buying an estimated $782M and bringing the position to 14,051,196 shares worth $3.06B. The position accounts for 0.46% of the portfolio, ranked #21.
UBS Group first reported a position in ABBV in Q4 2014 and has held it in 46 quarters since. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- UBS Group held 14,051,196 shares of AbbVie worth $3.06B as of Q1 2026.
- UBS Group bought 3,524,276 AbbVie shares in Q1 2026, an estimated $782M.
- AbbVie made up 0.46% of UBS Group's portfolio in Q1 2026, its #21 holding.
- UBS Group first reported a position in AbbVie in Q4 2014 and has held it in 46 quarters since.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.